Selective uptake of p-boronophenylalanine by osteosarcoma cells for boron neutron capture therapy

C. Ferrari, C. Zonta, L. Cansolino, A. M. Clerici, A. Gaspari, S. Altieri, S. Bortolussi, S. Stella, P. Bruschi, P. Dionigi, A. Zonta

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Osteosarcoma is the most common non-hematologic primary cancer type that develops in bone. Current osteosarcoma treatments combine multiagent chemotherapy with extensive surgical resection, which in some cases makes necessary the amputation of the entire limb. Nevertheless its infiltrative growth leads to a high incidence of local and distant recurrences that reduce the percentage of cured patients to less than 60%. These poor data required to set up a new therapeutic approach aimed to restrict the surgical removal meanwhile performing a radical treatment. Boron neutron capture therapy (BNCT), a particular radiotherapy based on the nuclear capture and fission reactions by atoms of 10B, when irradiated with thermal neutrons, could be a valid alternative or integrative option in case of osteosarcoma management, thanks to its peculiarity in selectively destroying neoplastic cells without damaging normal tissues. Aim of the present work is to investigate the feasibility of employing BNCT to treat the limb osteosarcoma. Boronophenylalanine (BPA) is used to carry 10B inside the neoplastic cells. As a first step the endocellular BPA uptake is tested in vitro on the UMR-106 osteosarcoma cell line. The results show an adequate accumulation capability. For the in vivo experiments, an animal tumor model is developed in Sprague-Dawley rats by means of an intrafemoral injection of UMR-106 cells at the condyle site. The absolute amounts of boron loading and the tumor to normal tissue 10B ratio are evaluated 2 h after the i.v. administration of BPA. The boron uptake by the neoplastic tissue is almost twice the normal one. However, higher values of boron concentration in tumor are requested before upholding BNCT as a valid therapeutic option in the treatment of osteosarcoma.

Original languageEnglish
JournalApplied Radiation and Isotopes
Volume67
Issue number7-8 SUPPL.
DOIs
Publication statusPublished - Jul 2009

Fingerprint

therapy
boron
neutrons
cells
tumors
limbs
nuclear capture
nuclear fission
chemotherapy
thermal neutrons
cultured cells
bones
rats
animals
radiation therapy
incidence
cancer
injection
atoms

Keywords

  • BNCT
  • BPA
  • Osteosarcoma
  • Rat
  • UMR-106 cell line

ASJC Scopus subject areas

  • Radiation

Cite this

Selective uptake of p-boronophenylalanine by osteosarcoma cells for boron neutron capture therapy. / Ferrari, C.; Zonta, C.; Cansolino, L.; Clerici, A. M.; Gaspari, A.; Altieri, S.; Bortolussi, S.; Stella, S.; Bruschi, P.; Dionigi, P.; Zonta, A.

In: Applied Radiation and Isotopes, Vol. 67, No. 7-8 SUPPL., 07.2009.

Research output: Contribution to journalArticle

Ferrari, C, Zonta, C, Cansolino, L, Clerici, AM, Gaspari, A, Altieri, S, Bortolussi, S, Stella, S, Bruschi, P, Dionigi, P & Zonta, A 2009, 'Selective uptake of p-boronophenylalanine by osteosarcoma cells for boron neutron capture therapy', Applied Radiation and Isotopes, vol. 67, no. 7-8 SUPPL.. https://doi.org/10.1016/j.apradiso.2009.03.059
Ferrari, C. ; Zonta, C. ; Cansolino, L. ; Clerici, A. M. ; Gaspari, A. ; Altieri, S. ; Bortolussi, S. ; Stella, S. ; Bruschi, P. ; Dionigi, P. ; Zonta, A. / Selective uptake of p-boronophenylalanine by osteosarcoma cells for boron neutron capture therapy. In: Applied Radiation and Isotopes. 2009 ; Vol. 67, No. 7-8 SUPPL.
@article{9c13f5b9d0ad43c6934de032361a0fcb,
title = "Selective uptake of p-boronophenylalanine by osteosarcoma cells for boron neutron capture therapy",
abstract = "Osteosarcoma is the most common non-hematologic primary cancer type that develops in bone. Current osteosarcoma treatments combine multiagent chemotherapy with extensive surgical resection, which in some cases makes necessary the amputation of the entire limb. Nevertheless its infiltrative growth leads to a high incidence of local and distant recurrences that reduce the percentage of cured patients to less than 60{\%}. These poor data required to set up a new therapeutic approach aimed to restrict the surgical removal meanwhile performing a radical treatment. Boron neutron capture therapy (BNCT), a particular radiotherapy based on the nuclear capture and fission reactions by atoms of 10B, when irradiated with thermal neutrons, could be a valid alternative or integrative option in case of osteosarcoma management, thanks to its peculiarity in selectively destroying neoplastic cells without damaging normal tissues. Aim of the present work is to investigate the feasibility of employing BNCT to treat the limb osteosarcoma. Boronophenylalanine (BPA) is used to carry 10B inside the neoplastic cells. As a first step the endocellular BPA uptake is tested in vitro on the UMR-106 osteosarcoma cell line. The results show an adequate accumulation capability. For the in vivo experiments, an animal tumor model is developed in Sprague-Dawley rats by means of an intrafemoral injection of UMR-106 cells at the condyle site. The absolute amounts of boron loading and the tumor to normal tissue 10B ratio are evaluated 2 h after the i.v. administration of BPA. The boron uptake by the neoplastic tissue is almost twice the normal one. However, higher values of boron concentration in tumor are requested before upholding BNCT as a valid therapeutic option in the treatment of osteosarcoma.",
keywords = "BNCT, BPA, Osteosarcoma, Rat, UMR-106 cell line",
author = "C. Ferrari and C. Zonta and L. Cansolino and Clerici, {A. M.} and A. Gaspari and S. Altieri and S. Bortolussi and S. Stella and P. Bruschi and P. Dionigi and A. Zonta",
year = "2009",
month = "7",
doi = "10.1016/j.apradiso.2009.03.059",
language = "English",
volume = "67",
journal = "Applied Radiation and Isotopes",
issn = "0969-8043",
publisher = "Elsevier Limited",
number = "7-8 SUPPL.",

}

TY - JOUR

T1 - Selective uptake of p-boronophenylalanine by osteosarcoma cells for boron neutron capture therapy

AU - Ferrari, C.

AU - Zonta, C.

AU - Cansolino, L.

AU - Clerici, A. M.

AU - Gaspari, A.

AU - Altieri, S.

AU - Bortolussi, S.

AU - Stella, S.

AU - Bruschi, P.

AU - Dionigi, P.

AU - Zonta, A.

PY - 2009/7

Y1 - 2009/7

N2 - Osteosarcoma is the most common non-hematologic primary cancer type that develops in bone. Current osteosarcoma treatments combine multiagent chemotherapy with extensive surgical resection, which in some cases makes necessary the amputation of the entire limb. Nevertheless its infiltrative growth leads to a high incidence of local and distant recurrences that reduce the percentage of cured patients to less than 60%. These poor data required to set up a new therapeutic approach aimed to restrict the surgical removal meanwhile performing a radical treatment. Boron neutron capture therapy (BNCT), a particular radiotherapy based on the nuclear capture and fission reactions by atoms of 10B, when irradiated with thermal neutrons, could be a valid alternative or integrative option in case of osteosarcoma management, thanks to its peculiarity in selectively destroying neoplastic cells without damaging normal tissues. Aim of the present work is to investigate the feasibility of employing BNCT to treat the limb osteosarcoma. Boronophenylalanine (BPA) is used to carry 10B inside the neoplastic cells. As a first step the endocellular BPA uptake is tested in vitro on the UMR-106 osteosarcoma cell line. The results show an adequate accumulation capability. For the in vivo experiments, an animal tumor model is developed in Sprague-Dawley rats by means of an intrafemoral injection of UMR-106 cells at the condyle site. The absolute amounts of boron loading and the tumor to normal tissue 10B ratio are evaluated 2 h after the i.v. administration of BPA. The boron uptake by the neoplastic tissue is almost twice the normal one. However, higher values of boron concentration in tumor are requested before upholding BNCT as a valid therapeutic option in the treatment of osteosarcoma.

AB - Osteosarcoma is the most common non-hematologic primary cancer type that develops in bone. Current osteosarcoma treatments combine multiagent chemotherapy with extensive surgical resection, which in some cases makes necessary the amputation of the entire limb. Nevertheless its infiltrative growth leads to a high incidence of local and distant recurrences that reduce the percentage of cured patients to less than 60%. These poor data required to set up a new therapeutic approach aimed to restrict the surgical removal meanwhile performing a radical treatment. Boron neutron capture therapy (BNCT), a particular radiotherapy based on the nuclear capture and fission reactions by atoms of 10B, when irradiated with thermal neutrons, could be a valid alternative or integrative option in case of osteosarcoma management, thanks to its peculiarity in selectively destroying neoplastic cells without damaging normal tissues. Aim of the present work is to investigate the feasibility of employing BNCT to treat the limb osteosarcoma. Boronophenylalanine (BPA) is used to carry 10B inside the neoplastic cells. As a first step the endocellular BPA uptake is tested in vitro on the UMR-106 osteosarcoma cell line. The results show an adequate accumulation capability. For the in vivo experiments, an animal tumor model is developed in Sprague-Dawley rats by means of an intrafemoral injection of UMR-106 cells at the condyle site. The absolute amounts of boron loading and the tumor to normal tissue 10B ratio are evaluated 2 h after the i.v. administration of BPA. The boron uptake by the neoplastic tissue is almost twice the normal one. However, higher values of boron concentration in tumor are requested before upholding BNCT as a valid therapeutic option in the treatment of osteosarcoma.

KW - BNCT

KW - BPA

KW - Osteosarcoma

KW - Rat

KW - UMR-106 cell line

UR - http://www.scopus.com/inward/record.url?scp=67649406020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649406020&partnerID=8YFLogxK

U2 - 10.1016/j.apradiso.2009.03.059

DO - 10.1016/j.apradiso.2009.03.059

M3 - Article

VL - 67

JO - Applied Radiation and Isotopes

JF - Applied Radiation and Isotopes

SN - 0969-8043

IS - 7-8 SUPPL.

ER -